Literature DB >> 35137140

Approach to the Patient With Lipodystrophy.

Lindsay T Fourman1, Steven K Grinspoon1.   

Abstract

Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, suggesting considerable underdiagnosis in clinical practice. In this article, we provide an overview of the etiology and management of generalized and partial lipodystrophy disorders. We bring together the latest scientific evidence and clinical guidelines and expose key gaps in knowledge. Through improved recognition of the lipodystrophy disorders, patients (and their affected family members) can be appropriately screened for cardiometabolic, noncardiometabolic, and syndromic abnormalities and undergo treatment with targeted interventions. Notably, insights gained through the study of this rare and extreme phenotype can inform our knowledge of more common disorders of adipose tissue overload, including generalized obesity.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Dunnigan variety lipodystrophy; HIV-associated lipodystrophy; lipodystrophy; metreleptin; tesamorelin

Mesh:

Substances:

Year:  2022        PMID: 35137140      PMCID: PMC9113814          DOI: 10.1210/clinem/dgac079

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   6.134


  101 in total

1.  Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Authors:  Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Lancet HIV       Date:  2019-10-11       Impact factor: 12.767

2.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

3.  Acquired lipodystrophy associated with immune checkpoint inhibitors.

Authors:  Subashini S Gnanendran; James A Miller; Christine A Archer; Swaranjali V Jain; Shelley J E Hwang; Geoffrey Peters; Andrew Miller
Journal:  Melanoma Res       Date:  2020-12       Impact factor: 3.599

4.  Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Authors:  Takara L Stanley; Julian Falutz; Christian Marsolais; Josée Morin; Graziella Soulban; Jean-Claude Mamputu; Hani Assaad; Ralph Turner; Steven K Grinspoon
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079

5.  Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation.

Authors:  Jean-Marc Schwarz; Kathleen Mulligan; Jeongae Lee; Joan C Lo; Michael Wen; Mustafa A Noor; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 6.  What lipodystrophies teach us about the metabolic syndrome.

Authors:  Jake P Mann; David B Savage
Journal:  J Clin Invest       Date:  2019-08-05       Impact factor: 14.808

Review 7.  Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.

Authors:  Michael E Røder
Journal:  Ther Adv Chronic Dis       Date:  2017-11-09       Impact factor: 5.091

8.  Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy.

Authors:  Masanori Adachi; Yumi Asakura; Koji Muroya; Hiroaki Goto; Hisato Kigasawa
Journal:  Clin Pediatr Endocrinol       Date:  2013-10-26

9.  Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Authors:  Lindsay T Fourman; James M Billingsley; George Agyapong; Shannan J Ho Sui; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Kathleen E Corey; Martin Torriani; David E Kleiner; Colleen M Hadigan; Takara L Stanley; Raymond T Chung; Steven K Grinspoon
Journal:  JCI Insight       Date:  2020-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.